The Oxford-Harrington Rare Disease Centre is a partnership between the University of Oxford and Harrington Discovery Institute in the US.
Our Mission
is to deliver new treatments for 400 million people affected by rare diseases worldwide
Our Goal
is to advance 40 drugs into clinical trials in the next 10 years
A Global Partnership
University of Oxford
The University of Oxford ranks number one in the Times Higher Education World University Rankings (2017 to 2023), and its Medical Sciences Division is consistently at the forefront of innovative and lifesaving science. The University has more than 250 principal investigator scientists working on over 350 rare diseases and cutting-edge technologies to accelerate drug development.
#1
in the world for medicine
Global research in 40
countries
>250
rare disease researchers
>300
spin outs
Harrington Discovery Institute
Harrington Discovery Institute at University Hospitals in Cleveland, Ohio is an international drug discovery and development organisation established to address unmet therapeutic need.
It provides comprehensive support to leading scholars and entrepreneurs across academic centres in the US, UK, and Canada, with a focus on medical breakthroughs that show great promise but would not otherwise advance to clinical trials.
By concentrating philanthropic, scientific and business development resources during the early, high-risk stage of development and creating milestone-driven pathways toward commercialisation, Harrington Discovery Institute de-risks therapeutic candidates in preparation for further investment.